Evidence map›Paper›PMID 32875153›Full record

ArticleAmerican journal of ophthalmology case reports2020

Necrotizing myositis in a rectus muscle arising in the setting of long-standing Langerhans cell histiocystosis and recent dabrafenib treatment.

Suzanne W van Landingham, Diane Puccetti, Heather Potter, David Gamm, Eli L Diamond, Mark J Lucarelli

Open access · goldAbstract readCase Reports
In one paragraph

Article in American journal of ophthalmology case reports, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.2field-weighted citation impact, top 44% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 3 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Suzanne W van LandinghamDepartment of Ophthalmology and Visual Sciences, University of Wisconsin-Madison, 2828 University Avenue, Madison, WI, 53705, USA.
Diane PuccettiDepartment of Pediatrics, American Family Children's Hospital University of Wisconsin-Madison, 1675 Highland Avenue, Madison, WI, 53792, USA.
Heather PotterDepartment of Ophthalmology and Visual Sciences, University of Wisconsin-Madison, 2828 University Avenue, Madison, WI, 53705, USA.
David GammDepartment of Ophthalmology and Visual Sciences, University of Wisconsin-Madison, 2828 University Avenue, Madison, WI, 53705, USA.
Eli L DiamondDepartment of Neurology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY, 10065, USA.
Mark J LucarelliDepartment of Ophthalmology and Visual Sciences, University of Wisconsin-Madison, 2828 University Avenue, Madison, WI, 53705, USA.
University of Wisconsin–Madison · USMemorial Sloan Kettering Cancer Center · US

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Hongbiao Carl Lekaye · 1985 to 2026
$347.4M
NCI NIH HHS P30 CA008748
6 · The paper itself

Abstract

purposeto describe an unusual case of necrotizing myositis in a rectus muscle, possibly related to BRAF inhibitor therapy. OBSERVATIONS: An 18-year old man with neurodegenerative Langerhans cell histiocytosis (LCH), recently started on the BRAF inhibitor dabrafenib, presented with right eye pain. Magnetic resonance imaging (MRI) orbits revealed a rectus muscle mass concerning for LCH recurrence or malignancy. Dabrafenib was stopped, and incisional biopsy of the mass was performed. The mass was absent on post-operative MRI, so no further treatment was pursued. Histopathologic evaluation was initially concerning for sarcoma, but on further analysis, appeared more consistent with necrotizing myositis. The mass did not recur, nor did the patient develop other signs or symptoms concerning for myositis or malignancy over a 24-month follow-up period.

conclusionsNecrotizing myositis has not been previously described in a rectus muscle or with BRAF inhibitor use, though myalgias and malignancies are established side effects. Necrotizing myositis may masquerade as sarcoma and should be on the differential diagnosis for a new mass in the setting of dabrafenib therapy.

Indexed as

braf inhibitorB-raf inhibitorDabrafenibLangerhans cell histiocytosisMassNecrotizing myopathyNecrotizing myositisOrbital myositisRectus muscleSarcoma

Identifiers

PMID32875153
PMCPMC7452147
OpenAlexW3049276902

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.